Advisory Services Network’s Crescent Biopharma CBIO Stock Holding History

Advisory Services Network’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-318	Closed	-$70K	–	1438
2021 Q3	$70K	Sell	318 -40	-11%	-$8.47K	﹤0.01%	1355
2021 Q2	$83K	Buy	+358	New	+$91.1K	﹤0.01%	1719

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Advisory Services Network's CBIO Position: Q4 2021 in Review

Advisory Services Network sold out of Crescent Biopharma (CBIO) in Q4 2021, closing a stake of 318 shares — an estimated $70K sold.

Advisory Services Network first reported a position in CBIO in Q2 2021 and held it in 2 quarters. The position peaked at $83K in Q2 2021. 47 funds tracked by Wall St. Rank hold CBIO as of Q4 2021.

Advisory Services Network reported no remaining Crescent Biopharma position as of Q4 2021 after selling out during the quarter.
Advisory Services Network sold 318 Crescent Biopharma shares in Q4 2021, an estimated $70K.
Advisory Services Network first reported a position in Crescent Biopharma in Q2 2021 and held it in 2 quarters.
Advisory Services Network's Crescent Biopharma position peaked at $83K in Q2 2021.
47 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2021.

Based on Advisory Services Network's 13F filing for Q4 2021, filed 14 Feb 2022.